- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07837674
Impact of Intravenous Dexamethasone on the Duration of Motor and Sensory Block Following Spinal Anesthesia With Chloroprocaine
The purpose of this study is to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Spinal anesthesia is commonly used for lower body surgery. The injection of local anesthetics in the lumbar intrathecal space allows the desensitization of the lower body by blocking sensory and motor nerve roots. In return, spinal anesthesia causes a sympathetic block which is associated with deleterious hemodynamic effects such as hypotension.
Isobaric chloroprocaine is a local anesthetic increasingly used for spinal anesthesia to reduce the duration of sensory and motor blocks compared to bupivacaine, allowing for faster postoperative recovery. However, certain medications used during surgery may possibly influence the duration of spinal anesthesia. Among these is dexamethasone, a drug belonging to the corticosteroid family. Dexamethasone is a well-known and commonly used medication in anesthesia to prevent postoperative nausea and vomiting. It is also used by anesthesiologists to reduce pain in the context of fast functional recovery after surgery. The safety of single-dose intravenous dexamethasone is therefore established in the context of anesthesia for several types of surgery.
Medical literature demonstrates that dexamethasone can prolong the effect of certain local anesthetics when administered intravenously or perineurally (near the nerves), and sometimes has no effect on the duration of local anesthetics administered for spinal anesthesia. Currently, no information is available in the literature on the effect of intravenous dexamethasone on the duration of a spinal anesthesia with isobaric chloroprocaine.
This study aims to compare the effect of a single dose of 8 mg of intravenous dexamethasone versus placebo on the duration of sensory and motor block after spinal anesthesia with chloroprocaine.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Julie Desroches, PhD
- Número de telefone: 24542 514-890-8000
- E-mail: anesthesie.recherche.chum@ssss.gouv.qc.ca
Estude backup de contato
- Nome: Stephan Williams, MD, PhD
- Número de telefone: 12132 514-890-8000
- E-mail: stephan.williams@umontreal.ca
Locais de estudo
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X 3E4
- Santé Québec - Centre hospitalier de l'Université de Montréal
-
Contato:
- Julie Desroches, PhD
- Número de telefone: 24542 514-890-8000
- E-mail: anesthesie.recherche.chum@ssss.gouv.qc.ca
-
Contato:
- Stephan Williams, MD, PhD
- Número de telefone: 12132 514-890-8000
- E-mail: stephan.williams@umontreal.ca
-
Investigador principal:
- Stephan Williams, MD, PhD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age between 18 and 90 years old
- ASA status I to III inclusively
- Planned lower body surgery under spinal anesthesia with chloroprocaine
- Signed informed consent form
Exclusion Criteria:
- Contraindication to spinal anesthesia: infection at the puncture site, congenital or acquired coagulopathy
- Preexisting neuropathy or nerve block that could interfere with study assessments
- Allergy or hypersensitivity to local anesthetics, dexamethasone, or other medications used in the study
- Preoperative use of corticosteroids
- Patient refusal
- Inability to consent
- Language barrier, psychiatric, physical, or mental condition making sensory and motor blocks assessment impossible despite prior instruction
- Administration of any intrathecal adjuvant (fentanyl, morphine, clonidine, dexmedetomidine, epinephrine, or others) along with chloroprocaine
- Perioperative intravenous dexmedetomidine administration
- Conversion to general anesthesia
- Impossible post-anesthesia care unit assessment: patient still intubated / transfer to intensive care unit, research team constraints, or other reasons
- Assessment in the recovery room impossible: medical condition (shock, delirium, major agitation, altered state of consciousness, or other), transfer to the intensive care unit, research team constraints, or other
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Intravenous dexamethasone
During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered intravenously over one minute. The study drug will be prepared by an independent assistant. |
Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia with chloprocaine
Outros nomes:
|
|
Comparador de Placebo: Intravenous normal saline
During the performance of spinal anesthesia using isobaric 1% chloroprocaine 50 mg, an intravenous infusion of 2 ml of Normal Saline will be initiated. The normal saline will be administered intravenously over one minute. The study drug will be prepared by an independent assistant. |
Administration of a single-dose of Normal saline during spinal anesthesia with chloprocaine
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Regression of sensory block by 2 dermatomes
Prazo: At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery
|
Loss of pinprick sensation by Von Frey filaments from the injection of chloroprocaine for spinal anesthesia until regression of the sensory block by two dermatomes from the peak sensory level |
At regression of spinal anesthesia by 2 dermatomes, approximately 60 minutes after surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Duration of motor block
Prazo: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
Using the Bromage scale from the time of injection of chloroprocaine for spinal anesthesia until complete recovery of motor block |
At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
|
Time until the first observable regression of the motor block
Prazo: At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
Time between the local anesthesic injection and the first measurable regression of the motor block measured using the Bromage scale. |
At 5,10,15 and 20 minutes following spinal anesthesia, then every 10 minutes until complete recovery, approximately 90 minutes after surgery
|
|
Onset of sensory block
Prazo: Up to 30 minutes following spinal anesthesia
|
Time from injection of chloroprocaine for spinal anesthesia to reduction of sensitivity using loss of pinprick sensation |
Up to 30 minutes following spinal anesthesia
|
|
Onset of motor block
Prazo: Up to 30 minutes following spinal anesthesia
|
Time from injection of chloroprocaine for spinal anesthesia to reduction of lower limbs movement using the Bromage scale |
Up to 30 minutes following spinal anesthesia
|
|
Quality of motor block
Prazo: Up to 30 minutes following spinal anesthesia
|
Maximal Bromage score The Bromage scale is a standardized tool used in neuraxial anesthesia to quantify motor block intensity in the lower extremities. It assesses a patient's ability to move their legs and feet. A scale of 0 to 3 is used: 0 - Full movement, 1- Partial block, 2 - Nearly complete block and 3 - Complete block. The maximal Bromage score reflects the deepest level of lower-limb motor block, with higher scores indicating stronger motor impairment and therefore a denser motor block. |
Up to 30 minutes following spinal anesthesia
|
|
Opioid consumption
Prazo: At recovery room discharge, approximately one hour after the end of surgery
|
Total dose of opioids |
At recovery room discharge, approximately one hour after the end of surgery
|
|
Antiemetic consumption
Prazo: At recovery room discharge, approximately one hour after the end of surgery
|
Total dose of antiemetics |
At recovery room discharge, approximately one hour after the end of surgery
|
|
Incidence of hypotension
Prazo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Systolic blood pressure lower than 90 mm Hg |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of bradycardia
Prazo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Heart rate slower than 50 beats per minute |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of nausea
Prazo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of nausea reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of vomiting
Prazo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of retching or vomiting reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of itching
Prazo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of itching reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of urinary retention
Prazo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of urinary retention reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of shivering
Prazo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of shivering reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Incidence of headache
Prazo: From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
Any episode of headache reported by the patient or nursing team |
From injection of chloroprocaine for spinal anesthesia to recovery room discharge, approximately one hour after the end of the surgery
|
|
Quality of postoperative recovery
Prazo: At 24 hours after the surgery
|
QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score), giving a lowest possible score of 0 (worst outcome), and a highest possible score of 150 (optimal outcome). |
At 24 hours after the surgery
|
|
Intensity of nausea/vomiting
Prazo: At 24 hours after surgery
|
Pre-established analysis of nausea/vomiting intensity at 24 hours based on the QoR-15 question. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score). |
At 24 hours after surgery
|
|
Pain intensity
Prazo: At 24 hours after surgery
|
Pre-established analysis of pain intensity at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score). |
At 24 hours after surgery
|
|
Quality of sleep
Prazo: At 24 hours after surgery
|
Pre-established analysis of sleep quality at 24 hours based on the QoR-15. QoR15 is a valid questionnaire to measure the quality of recovery after surgery and anaesthesia, which includes 15 questions. Each of the 15 items are scored by the patient from 0 (worst score) to 10 (optimal score). |
At 24 hours after surgery
|
|
Surgeon's satisfaction towards spinal anesthesia
Prazo: At the end of surgery, on the day of randomization
|
Unsatisfied or satisfied |
At the end of surgery, on the day of randomization
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Stephan Williams, MD, PhD, Santé Québec - CHUM
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Compostos de enxofre
- Produtos químicos orgânicos
- Preparações farmacêuticas
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Hidrocarbonetos, aromáticos
- Derivados de benzeno
- Soluções cristalóides
- Soluções isotônicas
- Soluções
- Ácidos sulfônicos
- Ácidos de enxofre
- Benzenosulfonatos
- Arilsulfonatos
- Ácidos arilsulfônicos
- Dobesilato de Cálcio
- Solução salina
Outros números de identificação do estudo
- 2027-13916
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .